| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 180 | 2024 | 5767 | 6.240 |
Why?
|
| Prostatectomy | 58 | 2024 | 962 | 3.510 |
Why?
|
| Prostate | 42 | 2024 | 1088 | 2.760 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 16 | 2021 | 425 | 1.730 |
Why?
|
| Prostate-Specific Antigen | 41 | 2020 | 993 | 1.340 |
Why?
|
| Kidney Transplantation | 11 | 2011 | 755 | 1.310 |
Why?
|
| Androgen Antagonists | 8 | 2020 | 411 | 1.260 |
Why?
|
| Receptors, Androgen | 17 | 2022 | 878 | 1.220 |
Why?
|
| Adenocarcinoma | 38 | 2022 | 7789 | 1.070 |
Why?
|
| Cyclosporine | 4 | 2011 | 278 | 0.890 |
Why?
|
| Male | 227 | 2024 | 123000 | 0.830 |
Why?
|
| Immunosuppressive Agents | 8 | 2023 | 1375 | 0.770 |
Why?
|
| Biomarkers, Tumor | 35 | 2020 | 10331 | 0.680 |
Why?
|
| Bone Neoplasms | 19 | 2021 | 2576 | 0.680 |
Why?
|
| Neoplasm Grading | 13 | 2019 | 1742 | 0.670 |
Why?
|
| Tumor Burden | 7 | 2019 | 1987 | 0.660 |
Why?
|
| Neoplasms, Hormone-Dependent | 5 | 2017 | 342 | 0.650 |
Why?
|
| Abiraterone Acetate | 5 | 2020 | 70 | 0.590 |
Why?
|
| Graft Rejection | 6 | 2009 | 834 | 0.580 |
Why?
|
| Antineoplastic Agents, Hormonal | 5 | 2017 | 840 | 0.580 |
Why?
|
| Middle Aged | 119 | 2022 | 86204 | 0.570 |
Why?
|
| Neuroendocrine Tumors | 3 | 2019 | 634 | 0.560 |
Why?
|
| Finasteride | 1 | 2016 | 31 | 0.560 |
Why?
|
| Cell Transdifferentiation | 1 | 2017 | 112 | 0.550 |
Why?
|
| Humans | 233 | 2024 | 261506 | 0.550 |
Why?
|
| Margins of Excision | 1 | 2017 | 285 | 0.550 |
Why?
|
| Biopsy | 24 | 2019 | 3443 | 0.510 |
Why?
|
| Propylene Glycols | 5 | 2005 | 36 | 0.510 |
Why?
|
| Hemangiosarcoma | 2 | 2009 | 234 | 0.500 |
Why?
|
| Phenylthiohydantoin | 4 | 2019 | 89 | 0.470 |
Why?
|
| Aged | 94 | 2021 | 70117 | 0.470 |
Why?
|
| Caveolin 1 | 4 | 2017 | 204 | 0.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 26 | 2021 | 8873 | 0.430 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2008 | 256 | 0.400 |
Why?
|
| Watchful Waiting | 3 | 2019 | 289 | 0.390 |
Why?
|
| Matrix Metalloproteinase 9 | 3 | 2008 | 360 | 0.390 |
Why?
|
| Antineoplastic Agents | 16 | 2023 | 14289 | 0.380 |
Why?
|
| Poly(ADP-ribose) Polymerases | 4 | 2021 | 324 | 0.370 |
Why?
|
| Nitrofurazone | 1 | 2010 | 2 | 0.370 |
Why?
|
| Cadherins | 5 | 2008 | 660 | 0.370 |
Why?
|
| Kupffer Cells | 4 | 1999 | 42 | 0.360 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 4 | 2019 | 479 | 0.360 |
Why?
|
| Immunohistochemistry | 31 | 2017 | 7548 | 0.350 |
Why?
|
| Disease Progression | 27 | 2019 | 6682 | 0.350 |
Why?
|
| Androgens | 10 | 2022 | 511 | 0.350 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2020 | 10035 | 0.350 |
Why?
|
| Ultrasound, High-Intensity Focused, Transrectal | 1 | 2009 | 7 | 0.350 |
Why?
|
| Biopsy, Needle | 11 | 2009 | 1363 | 0.340 |
Why?
|
| Living Donors | 5 | 2010 | 171 | 0.330 |
Why?
|
| Kidney | 8 | 2015 | 2146 | 0.320 |
Why?
|
| Phthalazines | 4 | 2021 | 253 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2021 | 15862 | 0.320 |
Why?
|
| Carcinoma, Small Cell | 5 | 2014 | 408 | 0.310 |
Why?
|
| Prognosis | 26 | 2020 | 21713 | 0.310 |
Why?
|
| Cryosurgery | 1 | 2009 | 167 | 0.300 |
Why?
|
| Adult | 54 | 2021 | 77950 | 0.300 |
Why?
|
| Cell Line, Tumor | 25 | 2022 | 14551 | 0.290 |
Why?
|
| Neoplasm Metastasis | 17 | 2021 | 5112 | 0.280 |
Why?
|
| Reperfusion Injury | 4 | 2005 | 145 | 0.280 |
Why?
|
| Chagas Disease | 1 | 2010 | 277 | 0.280 |
Why?
|
| Obesity | 4 | 2024 | 2884 | 0.280 |
Why?
|
| Taxoids | 4 | 2019 | 967 | 0.270 |
Why?
|
| Retrospective Studies | 25 | 2024 | 37905 | 0.270 |
Why?
|
| Animals | 54 | 2022 | 59536 | 0.270 |
Why?
|
| Ki-67 Antigen | 6 | 2014 | 666 | 0.270 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 5 | 2011 | 84 | 0.270 |
Why?
|
| Tumor Microenvironment | 7 | 2023 | 2864 | 0.260 |
Why?
|
| DNA Damage | 4 | 2017 | 1954 | 0.260 |
Why?
|
| Carcinoma, Neuroendocrine | 3 | 2017 | 716 | 0.260 |
Why?
|
| Mice | 36 | 2022 | 34495 | 0.250 |
Why?
|
| Testicular Neoplasms | 3 | 2006 | 529 | 0.250 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2021 | 3821 | 0.250 |
Why?
|
| Treatment Outcome | 26 | 2020 | 32848 | 0.240 |
Why?
|
| Neoplasm Staging | 32 | 2019 | 13658 | 0.240 |
Why?
|
| Salvage Therapy | 2 | 2012 | 2054 | 0.240 |
Why?
|
| Tumor Cells, Cultured | 17 | 2021 | 5395 | 0.240 |
Why?
|
| RNA, Messenger | 7 | 2012 | 6150 | 0.240 |
Why?
|
| Benzamides | 8 | 2019 | 1832 | 0.240 |
Why?
|
| Piperazines | 6 | 2021 | 2101 | 0.240 |
Why?
|
| Body Weights and Measures | 1 | 2003 | 52 | 0.240 |
Why?
|
| Urinary Bladder Neoplasms | 10 | 2017 | 2341 | 0.230 |
Why?
|
| Graft Survival | 4 | 2009 | 1062 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 7 | 2017 | 4975 | 0.230 |
Why?
|
| Prednisone | 3 | 2020 | 984 | 0.230 |
Why?
|
| Histocompatibility Testing | 4 | 2010 | 447 | 0.220 |
Why?
|
| Cell Separation | 2 | 2010 | 612 | 0.220 |
Why?
|
| Mycophenolic Acid | 1 | 2003 | 148 | 0.220 |
Why?
|
| Terminology as Topic | 3 | 2014 | 414 | 0.220 |
Why?
|
| PTEN Phosphohydrolase | 4 | 2017 | 986 | 0.220 |
Why?
|
| Logistic Models | 11 | 2017 | 3441 | 0.220 |
Why?
|
| Adrenal Medulla | 1 | 2002 | 17 | 0.220 |
Why?
|
| Myelolipoma | 1 | 2002 | 12 | 0.220 |
Why?
|
| Ganglioneuroma | 1 | 2002 | 41 | 0.210 |
Why?
|
| Signal Transduction | 14 | 2021 | 11965 | 0.210 |
Why?
|
| Weight Gain | 1 | 2005 | 464 | 0.210 |
Why?
|
| Mice, Nude | 12 | 2021 | 4307 | 0.210 |
Why?
|
| Aggression | 1 | 2024 | 252 | 0.200 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 960 | 0.200 |
Why?
|
| Androstenes | 3 | 2020 | 41 | 0.200 |
Why?
|
| Predictive Value of Tests | 18 | 2017 | 4892 | 0.200 |
Why?
|
| Follow-Up Studies | 15 | 2020 | 14889 | 0.200 |
Why?
|
| Neuroectodermal Tumors | 1 | 2021 | 35 | 0.200 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2005 | 489 | 0.200 |
Why?
|
| Prostatic Hyperplasia | 9 | 2001 | 210 | 0.200 |
Why?
|
| Disease Models, Animal | 10 | 2019 | 7222 | 0.200 |
Why?
|
| N-Myc Proto-Oncogene Protein | 2 | 2019 | 82 | 0.200 |
Why?
|
| Cell Differentiation | 7 | 2021 | 4078 | 0.200 |
Why?
|
| Ploidies | 4 | 1999 | 248 | 0.200 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2011 | 755 | 0.190 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2017 | 112 | 0.190 |
Why?
|
| Neoplasm Proteins | 4 | 2015 | 3230 | 0.190 |
Why?
|
| Orchiectomy | 6 | 2013 | 214 | 0.190 |
Why?
|
| Oxygen | 3 | 1997 | 754 | 0.190 |
Why?
|
| Ipilimumab | 4 | 2020 | 710 | 0.190 |
Why?
|
| Antigens, Neoplasm | 5 | 2015 | 1506 | 0.190 |
Why?
|
| Learning Curve | 1 | 2021 | 68 | 0.190 |
Why?
|
| Prospective Studies | 16 | 2020 | 12873 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 129 | 0.190 |
Why?
|
| Rectal Neoplasms | 1 | 2009 | 1202 | 0.190 |
Why?
|
| Hedgehog Proteins | 3 | 2012 | 424 | 0.190 |
Why?
|
| Anilides | 2 | 2020 | 268 | 0.190 |
Why?
|
| Cohort Studies | 13 | 2020 | 9244 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 198 | 0.180 |
Why?
|
| Body Mass Index | 3 | 2024 | 2203 | 0.180 |
Why?
|
| Overweight | 1 | 2024 | 484 | 0.180 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 173 | 0.180 |
Why?
|
| Time Factors | 15 | 2017 | 12926 | 0.180 |
Why?
|
| Gene Expression Profiling | 12 | 2021 | 5159 | 0.180 |
Why?
|
| Antigens, CD | 3 | 2010 | 1385 | 0.180 |
Why?
|
| Castration | 4 | 2014 | 122 | 0.180 |
Why?
|
| Radium | 1 | 2021 | 93 | 0.180 |
Why?
|
| Sphingosine | 5 | 2005 | 55 | 0.180 |
Why?
|
| Neoplasms, Complex and Mixed | 2 | 2017 | 43 | 0.180 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2021 | 209 | 0.180 |
Why?
|
| Ischemia | 4 | 1995 | 391 | 0.170 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2015 | 1823 | 0.170 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 1998 | 193 | 0.170 |
Why?
|
| Bone Marrow Neoplasms | 3 | 2014 | 132 | 0.170 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 135 | 0.170 |
Why?
|
| Precision Medicine | 2 | 2020 | 1154 | 0.170 |
Why?
|
| Apoptosis | 12 | 2021 | 7591 | 0.170 |
Why?
|
| Carcinoma, Ductal | 1 | 2020 | 145 | 0.170 |
Why?
|
| Cryotherapy | 1 | 1999 | 67 | 0.170 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 1995 | 19 | 0.160 |
Why?
|
| Transplantation, Heterologous | 9 | 2012 | 1082 | 0.160 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2019 | 167 | 0.160 |
Why?
|
| Pyridines | 3 | 2021 | 1244 | 0.160 |
Why?
|
| Brachytherapy | 2 | 2017 | 977 | 0.160 |
Why?
|
| Testosterone | 6 | 2022 | 619 | 0.160 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 338 | 0.160 |
Why?
|
| Transplantation Immunology | 1 | 1998 | 97 | 0.160 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2003 | 925 | 0.160 |
Why?
|
| Preoperative Care | 5 | 2019 | 1529 | 0.160 |
Why?
|
| Clonal Evolution | 1 | 2020 | 253 | 0.160 |
Why?
|
| Iron Overload | 1 | 1998 | 35 | 0.160 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2021 | 182 | 0.160 |
Why?
|
| Image-Guided Biopsy | 1 | 2021 | 327 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 5 | 2023 | 4367 | 0.160 |
Why?
|
| Genes, Tumor Suppressor | 3 | 1999 | 1064 | 0.160 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 2 | 2014 | 36 | 0.160 |
Why?
|
| DNA, Neoplasm | 6 | 2000 | 1910 | 0.160 |
Why?
|
| Nerve Tissue Proteins | 3 | 2012 | 1491 | 0.160 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2020 | 224 | 0.160 |
Why?
|
| Carcinoma | 8 | 2008 | 2578 | 0.150 |
Why?
|
| Mice, SCID | 7 | 2019 | 1869 | 0.150 |
Why?
|
| Risk Assessment | 10 | 2020 | 6869 | 0.150 |
Why?
|
| Selenomethionine | 2 | 2009 | 41 | 0.150 |
Why?
|
| Pyruvic Acid | 1 | 2019 | 133 | 0.150 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2019 | 310 | 0.150 |
Why?
|
| Insecticides | 1 | 1997 | 49 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-myb | 2 | 2014 | 47 | 0.150 |
Why?
|
| Lactic Acid | 1 | 2019 | 305 | 0.150 |
Why?
|
| DNA Helicases | 2 | 2017 | 434 | 0.150 |
Why?
|
| Thiophenes | 2 | 2017 | 148 | 0.150 |
Why?
|
| Interleukin-11 Receptor alpha Subunit | 2 | 2015 | 14 | 0.150 |
Why?
|
| Genes, Essential | 1 | 2017 | 48 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2011 | 810 | 0.150 |
Why?
|
| Analysis of Variance | 6 | 2017 | 2307 | 0.150 |
Why?
|
| Multivariate Analysis | 10 | 2017 | 4298 | 0.150 |
Why?
|
| BRCA1 Protein | 2 | 2017 | 493 | 0.140 |
Why?
|
| Patient Selection | 4 | 2018 | 2055 | 0.140 |
Why?
|
| B7 Antigens | 1 | 2017 | 84 | 0.140 |
Why?
|
| Urea | 2 | 2017 | 290 | 0.140 |
Why?
|
| Blood Vessels | 2 | 2011 | 217 | 0.140 |
Why?
|
| Chemokine CXCL1 | 1 | 2016 | 60 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2022 | 7702 | 0.140 |
Why?
|
| Creatinine | 5 | 2009 | 531 | 0.140 |
Why?
|
| Aged, 80 and over | 24 | 2020 | 29902 | 0.140 |
Why?
|
| Chemokine CXCL5 | 1 | 2015 | 13 | 0.140 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2017 | 174 | 0.140 |
Why?
|
| Cell Proliferation | 8 | 2021 | 7226 | 0.140 |
Why?
|
| Chile | 2 | 2016 | 61 | 0.140 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2019 | 624 | 0.140 |
Why?
|
| Electroencephalography | 1 | 2020 | 898 | 0.140 |
Why?
|
| Benzimidazoles | 2 | 2021 | 428 | 0.140 |
Why?
|
| Cell Cycle Proteins | 2 | 2017 | 2045 | 0.140 |
Why?
|
| Aurora Kinase A | 2 | 2017 | 202 | 0.140 |
Why?
|
| Gene Expression | 4 | 2021 | 3570 | 0.140 |
Why?
|
| Genetic Markers | 5 | 2009 | 974 | 0.140 |
Why?
|
| Drug Monitoring | 2 | 2011 | 333 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2002 | 317 | 0.140 |
Why?
|
| Arsenic | 1 | 2016 | 49 | 0.130 |
Why?
|
| Mitosis | 3 | 2017 | 615 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 7 | 2016 | 1547 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-yes | 1 | 2015 | 23 | 0.130 |
Why?
|
| Carcinoma, Transitional Cell | 4 | 2010 | 962 | 0.130 |
Why?
|
| Antibodies | 4 | 2015 | 838 | 0.130 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 1301 | 0.130 |
Why?
|
| Patient Care Team | 1 | 2021 | 795 | 0.130 |
Why?
|
| Rats | 12 | 2005 | 6086 | 0.130 |
Why?
|
| Nuclear Proteins | 3 | 2017 | 3343 | 0.130 |
Why?
|
| Loss of Heterozygosity | 3 | 2002 | 602 | 0.130 |
Why?
|
| Introns | 2 | 2015 | 432 | 0.130 |
Why?
|
| Fingolimod Hydrochloride | 5 | 2005 | 45 | 0.130 |
Why?
|
| Cadaver | 3 | 2009 | 237 | 0.130 |
Why?
|
| Leprosy, Lepromatous | 1 | 1994 | 12 | 0.130 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2015 | 111 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2011 | 852 | 0.120 |
Why?
|
| Smad4 Protein | 1 | 2015 | 196 | 0.120 |
Why?
|
| Seizures | 1 | 2020 | 989 | 0.120 |
Why?
|
| Carcinoma, Large Cell | 2 | 2014 | 94 | 0.120 |
Why?
|
| Interferon-gamma | 2 | 2009 | 1144 | 0.120 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2017 | 287 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2009 | 4938 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2003 | 2063 | 0.120 |
Why?
|
| Survival Rate | 6 | 2021 | 12221 | 0.120 |
Why?
|
| Myeloid Cells | 1 | 2015 | 269 | 0.120 |
Why?
|
| Environmental Exposure | 1 | 2016 | 288 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 8 | 2019 | 3981 | 0.120 |
Why?
|
| Genes, p53 | 4 | 2004 | 1090 | 0.120 |
Why?
|
| DNA-Binding Proteins | 5 | 2017 | 4821 | 0.120 |
Why?
|
| Up-Regulation | 6 | 2021 | 2450 | 0.120 |
Why?
|
| Diagnostic Imaging | 1 | 2021 | 1162 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2020 | 5178 | 0.110 |
Why?
|
| Quinolones | 1 | 2014 | 160 | 0.110 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2005 | 248 | 0.110 |
Why?
|
| Disease-Free Survival | 10 | 2016 | 10001 | 0.110 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2012 | 14 | 0.110 |
Why?
|
| Renal Veins | 2 | 2009 | 56 | 0.110 |
Why?
|
| Oxyhemoglobins | 1 | 1992 | 25 | 0.110 |
Why?
|
| Drug Therapy, Combination | 4 | 2020 | 2315 | 0.110 |
Why?
|
| Nitriles | 4 | 2019 | 906 | 0.110 |
Why?
|
| Lipoxygenases | 1 | 2012 | 5 | 0.110 |
Why?
|
| Gene Deletion | 3 | 2001 | 1442 | 0.110 |
Why?
|
| Ultrasonography | 7 | 2007 | 1863 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 5437 | 0.110 |
Why?
|
| Tissue Array Analysis | 4 | 2017 | 760 | 0.110 |
Why?
|
| Bone Marrow Cells | 1 | 2016 | 943 | 0.110 |
Why?
|
| Lipids | 1 | 2016 | 644 | 0.110 |
Why?
|
| Arachidonic Acid | 1 | 2012 | 118 | 0.110 |
Why?
|
| Androstenols | 1 | 2011 | 10 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 1265 | 0.110 |
Why?
|
| Peptides | 2 | 2015 | 1479 | 0.100 |
Why?
|
| Pathology, Surgical | 2 | 1997 | 81 | 0.100 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 2010 | 167 | 0.100 |
Why?
|
| Aspartate-Ammonia Ligase | 1 | 2012 | 21 | 0.100 |
Why?
|
| Bone Marrow | 5 | 2014 | 2358 | 0.100 |
Why?
|
| Progesterone | 1 | 2014 | 513 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2016 | 1544 | 0.100 |
Why?
|
| Fatal Outcome | 2 | 2017 | 829 | 0.100 |
Why?
|
| Double-Blind Method | 2 | 2016 | 2588 | 0.100 |
Why?
|
| Liver | 3 | 1999 | 2961 | 0.100 |
Why?
|
| Cluster Analysis | 2 | 2015 | 1053 | 0.100 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1994 | 272 | 0.100 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 481 | 0.100 |
Why?
|
| Macrophages | 2 | 2017 | 1304 | 0.100 |
Why?
|
| Cell Movement | 2 | 2016 | 2466 | 0.100 |
Why?
|
| Glucuronosyltransferase | 1 | 2012 | 104 | 0.100 |
Why?
|
| Prostatic Diseases | 2 | 2006 | 30 | 0.100 |
Why?
|
| Gene Fusion | 2 | 2010 | 209 | 0.100 |
Why?
|
| Autocrine Communication | 1 | 2011 | 84 | 0.100 |
Why?
|
| Autoantibodies | 1 | 2015 | 576 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 6 | 2010 | 3203 | 0.100 |
Why?
|
| Medical Records | 2 | 1997 | 415 | 0.100 |
Why?
|
| Proteins | 1 | 2019 | 1963 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 1258 | 0.100 |
Why?
|
| Lymphatic Metastasis | 10 | 2018 | 4844 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2016 | 717 | 0.100 |
Why?
|
| Osteoblasts | 3 | 2014 | 370 | 0.100 |
Why?
|
| Heterografts | 3 | 2019 | 733 | 0.090 |
Why?
|
| Regression Analysis | 3 | 2011 | 1546 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 1249 | 0.090 |
Why?
|
| Random Allocation | 2 | 2020 | 703 | 0.090 |
Why?
|
| Societies, Medical | 4 | 2005 | 1335 | 0.090 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2009 | 148 | 0.090 |
Why?
|
| Lymph Node Excision | 1 | 2018 | 1959 | 0.090 |
Why?
|
| Soft Tissue Neoplasms | 2 | 1988 | 882 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2009 | 4988 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 483 | 0.090 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 57 | 0.090 |
Why?
|
| B7-H1 Antigen | 1 | 2017 | 1022 | 0.090 |
Why?
|
| Female | 25 | 2020 | 141928 | 0.090 |
Why?
|
| Family Characteristics | 1 | 2010 | 102 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 7 | 3 | 1996 | 234 | 0.090 |
Why?
|
| L-Lactate Dehydrogenase | 4 | 1999 | 299 | 0.090 |
Why?
|
| HLA-DR Antigens | 1 | 2010 | 173 | 0.090 |
Why?
|
| Postoperative Complications | 6 | 2018 | 5542 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 534 | 0.090 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 102 | 0.090 |
Why?
|
| RNA, Long Noncoding | 1 | 2015 | 598 | 0.090 |
Why?
|
| Peptide Library | 3 | 2011 | 158 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2019 | 2669 | 0.090 |
Why?
|
| Gallbladder Neoplasms | 2 | 2002 | 245 | 0.090 |
Why?
|
| Risk Factors | 7 | 2018 | 17523 | 0.090 |
Why?
|
| Microdissection | 2 | 2009 | 86 | 0.090 |
Why?
|
| Quality of Life | 2 | 2017 | 4532 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 3 | 2017 | 2330 | 0.090 |
Why?
|
| Interleukin-8 | 2 | 2016 | 519 | 0.080 |
Why?
|
| Protein Isoforms | 3 | 2014 | 842 | 0.080 |
Why?
|
| alpha-Tocopherol | 1 | 2009 | 78 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2017 | 992 | 0.080 |
Why?
|
| Emulsions | 1 | 2009 | 82 | 0.080 |
Why?
|
| Fibroblast Growth Factor 9 | 1 | 2008 | 20 | 0.080 |
Why?
|
| Sural Nerve | 1 | 2008 | 54 | 0.080 |
Why?
|
| Age Factors | 5 | 2010 | 5377 | 0.080 |
Why?
|
| Gadolinium | 3 | 1999 | 164 | 0.080 |
Why?
|
| Phosphorylation | 5 | 2017 | 4804 | 0.080 |
Why?
|
| Mice, Transgenic | 5 | 2016 | 4143 | 0.080 |
Why?
|
| Penile Erection | 1 | 2008 | 86 | 0.080 |
Why?
|
| Keratins | 7 | 2008 | 330 | 0.080 |
Why?
|
| Combined Modality Therapy | 5 | 2011 | 8865 | 0.080 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 1988 | 22 | 0.080 |
Why?
|
| Carbon | 2 | 1999 | 149 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 1866 | 0.080 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2005 | 221 | 0.080 |
Why?
|
| Carcinoid Tumor | 3 | 2014 | 280 | 0.080 |
Why?
|
| beta Catenin | 1 | 2012 | 688 | 0.080 |
Why?
|
| Primary Cell Culture | 2 | 2020 | 208 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2015 | 3639 | 0.080 |
Why?
|
| S Phase | 2 | 1999 | 281 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2011 | 612 | 0.080 |
Why?
|
| Reproducibility of Results | 8 | 2009 | 6009 | 0.080 |
Why?
|
| Tissue Donors | 2 | 2009 | 769 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2009 | 3552 | 0.080 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2007 | 104 | 0.080 |
Why?
|
| Oxygen Consumption | 2 | 1999 | 401 | 0.070 |
Why?
|
| Organ Size | 5 | 2007 | 690 | 0.070 |
Why?
|
| Neoplasm Transplantation | 4 | 2010 | 1519 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2010 | 1033 | 0.070 |
Why?
|
| Area Under Curve | 1 | 2009 | 700 | 0.070 |
Why?
|
| Lymph Nodes | 3 | 2018 | 2967 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 3 | 2019 | 1290 | 0.070 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 362 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2011 | 2803 | 0.070 |
Why?
|
| Osteogenesis | 1 | 2008 | 271 | 0.070 |
Why?
|
| Nephrectomy | 2 | 2009 | 779 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 2508 | 0.070 |
Why?
|
| Diagnosis, Differential | 8 | 2006 | 4744 | 0.070 |
Why?
|
| Carcinoma in Situ | 3 | 1997 | 487 | 0.070 |
Why?
|
| Erectile Dysfunction | 1 | 2008 | 212 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 1225 | 0.070 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2007 | 129 | 0.070 |
Why?
|
| Receptors, Interleukin-8B | 2 | 2016 | 56 | 0.070 |
Why?
|
| Chromosome Fragile Sites | 1 | 2005 | 38 | 0.070 |
Why?
|
| Epithelial Cells | 4 | 2007 | 1818 | 0.070 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2019 | 192 | 0.070 |
Why?
|
| Physical Examination | 1 | 2007 | 299 | 0.070 |
Why?
|
| Molecular Sequence Data | 6 | 2015 | 6089 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 446 | 0.070 |
Why?
|
| Flow Cytometry | 8 | 2017 | 3033 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 502 | 0.070 |
Why?
|
| Immunotherapy | 2 | 2017 | 3341 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 2009 | 462 | 0.070 |
Why?
|
| Nomograms | 1 | 2007 | 313 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2021 | 1648 | 0.070 |
Why?
|
| DNA Copy Number Variations | 3 | 2020 | 1516 | 0.070 |
Why?
|
| Hemoglobins | 1 | 2007 | 477 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2009 | 544 | 0.060 |
Why?
|
| Pericytes | 1 | 2005 | 96 | 0.060 |
Why?
|
| Cell Nucleus | 3 | 2014 | 1620 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 6 | 2002 | 1165 | 0.060 |
Why?
|
| Vitamin E | 1 | 2005 | 136 | 0.060 |
Why?
|
| Precancerous Conditions | 2 | 2002 | 1058 | 0.060 |
Why?
|
| Fibroblast Growth Factor 2 | 3 | 2014 | 223 | 0.060 |
Why?
|
| Computer Simulation | 3 | 1999 | 1529 | 0.060 |
Why?
|
| Neoplasms | 4 | 2017 | 15193 | 0.060 |
Why?
|
| Genes, erbB | 1 | 2004 | 26 | 0.060 |
Why?
|
| Leuprolide | 2 | 2014 | 65 | 0.060 |
Why?
|
| Acute Disease | 3 | 1999 | 2422 | 0.060 |
Why?
|
| Trisomy | 2 | 1996 | 231 | 0.060 |
Why?
|
| Drug Administration Schedule | 4 | 2015 | 3472 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2008 | 673 | 0.060 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2020 | 691 | 0.060 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2017 | 278 | 0.060 |
Why?
|
| Sensitivity and Specificity | 5 | 2019 | 4971 | 0.060 |
Why?
|
| In Situ Hybridization | 5 | 2005 | 1037 | 0.060 |
Why?
|
| Receptors, Interleukin | 1 | 2004 | 97 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2017 | 1313 | 0.060 |
Why?
|
| Receptor, ErbB-3 | 1 | 2004 | 122 | 0.060 |
Why?
|
| Dogs | 2 | 1998 | 1155 | 0.060 |
Why?
|
| Blotting, Western | 5 | 2012 | 3536 | 0.060 |
Why?
|
| Renal Circulation | 1 | 2003 | 60 | 0.060 |
Why?
|
| Thalidomide | 1 | 2007 | 569 | 0.060 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2004 | 161 | 0.060 |
Why?
|
| Cyclins | 2 | 2002 | 456 | 0.060 |
Why?
|
| Melanoma | 2 | 2018 | 5317 | 0.060 |
Why?
|
| Doxorubicin | 3 | 2006 | 3005 | 0.060 |
Why?
|
| ROC Curve | 3 | 2020 | 1183 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 1443 | 0.060 |
Why?
|
| Antilymphocyte Serum | 1 | 2003 | 228 | 0.060 |
Why?
|
| Mutation | 8 | 2015 | 15179 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2011 | 2291 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2018 | 1489 | 0.050 |
Why?
|
| Bone and Bones | 2 | 2014 | 619 | 0.050 |
Why?
|
| Antioxidants | 1 | 2005 | 507 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 2003 | 1493 | 0.050 |
Why?
|
| Antibodies, Neoplasm | 1 | 2002 | 259 | 0.050 |
Why?
|
| Ubiquitination | 2 | 2017 | 575 | 0.050 |
Why?
|
| Feasibility Studies | 3 | 2009 | 2292 | 0.050 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2017 | 163 | 0.050 |
Why?
|
| Epothilones | 1 | 2001 | 54 | 0.050 |
Why?
|
| Macrolides | 1 | 2001 | 62 | 0.050 |
Why?
|
| Observer Variation | 2 | 2001 | 671 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2021 | 2084 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2006 | 1996 | 0.050 |
Why?
|
| Blood Flow Velocity | 2 | 1992 | 475 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 1586 | 0.050 |
Why?
|
| Cisplatin | 2 | 2006 | 2432 | 0.050 |
Why?
|
| Lung Neoplasms | 4 | 2020 | 11538 | 0.050 |
Why?
|
| CTLA-4 Antigen | 3 | 2010 | 657 | 0.050 |
Why?
|
| Renal Artery | 2 | 2009 | 79 | 0.050 |
Why?
|
| Steroids | 1 | 2022 | 356 | 0.050 |
Why?
|
| Kidney Function Tests | 2 | 2005 | 192 | 0.050 |
Why?
|
| Drug Combinations | 2 | 2019 | 621 | 0.050 |
Why?
|
| Collagenases | 1 | 2000 | 74 | 0.050 |
Why?
|
| Polymorphism, Genetic | 2 | 2004 | 1450 | 0.050 |
Why?
|
| Penile Neoplasms | 1 | 2002 | 161 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 2 | 2011 | 577 | 0.050 |
Why?
|
| RNA | 2 | 2021 | 1013 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2021 | 257 | 0.050 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2020 | 94 | 0.050 |
Why?
|
| Phagocytosis | 2 | 1999 | 260 | 0.040 |
Why?
|
| Reference Values | 4 | 2004 | 1099 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 709 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2003 | 2488 | 0.040 |
Why?
|
| Sequence Deletion | 2 | 2020 | 875 | 0.040 |
Why?
|
| Hemagglutinins | 1 | 1999 | 39 | 0.040 |
Why?
|
| Transfection | 3 | 2015 | 2944 | 0.040 |
Why?
|
| Adenoma | 1 | 2005 | 716 | 0.040 |
Why?
|
| Indolizines | 1 | 2019 | 45 | 0.040 |
Why?
|
| DNA | 2 | 2022 | 2693 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2009 | 1225 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 2000 | 197 | 0.040 |
Why?
|
| Povidone | 1 | 1999 | 13 | 0.040 |
Why?
|
| Fatigue | 2 | 2019 | 1239 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2019 | 34 | 0.040 |
Why?
|
| Perfusion | 2 | 1999 | 293 | 0.040 |
Why?
|
| Growth Substances | 2 | 1998 | 300 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 1999 | 141 | 0.040 |
Why?
|
| Glutathione | 3 | 1999 | 368 | 0.040 |
Why?
|
| Lymphokines | 1 | 2000 | 272 | 0.040 |
Why?
|
| Pyridinium Compounds | 1 | 2019 | 63 | 0.040 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2019 | 61 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2021 | 212 | 0.040 |
Why?
|
| Ketoconazole | 2 | 2014 | 34 | 0.040 |
Why?
|
| Hypokalemia | 1 | 2019 | 55 | 0.040 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 2 | 2010 | 76 | 0.040 |
Why?
|
| Cyclic N-Oxides | 1 | 2019 | 106 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 2 | 2012 | 1077 | 0.040 |
Why?
|
| Dehydration | 1 | 2019 | 87 | 0.040 |
Why?
|
| Carcinoma, Papillary | 1 | 2003 | 584 | 0.040 |
Why?
|
| Membrane Proteins | 3 | 2017 | 2819 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 1994 | 3976 | 0.040 |
Why?
|
| Leptin | 1 | 2001 | 295 | 0.040 |
Why?
|
| Microscopy, Electron | 3 | 1992 | 600 | 0.040 |
Why?
|
| Radiography | 1 | 2003 | 1904 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2015 | 1391 | 0.040 |
Why?
|
| Status Epilepticus | 1 | 2020 | 145 | 0.040 |
Why?
|
| Infusions, Intravenous | 3 | 2011 | 1382 | 0.040 |
Why?
|
| Thorax | 1 | 2020 | 213 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2017 | 1062 | 0.040 |
Why?
|
| Moclobemide | 2 | 1995 | 2 | 0.040 |
Why?
|
| United States | 3 | 2017 | 15433 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 1999 | 137 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 1999 | 238 | 0.040 |
Why?
|
| Anorexia | 1 | 2019 | 143 | 0.040 |
Why?
|
| Rectum | 1 | 2021 | 467 | 0.040 |
Why?
|
| Disease Management | 2 | 2019 | 1052 | 0.040 |
Why?
|
| Receptors, Bombesin | 1 | 1998 | 11 | 0.040 |
Why?
|
| E2F1 Transcription Factor | 1 | 2019 | 206 | 0.040 |
Why?
|
| Copper | 1 | 1999 | 165 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2019 | 344 | 0.040 |
Why?
|
| Young Adult | 3 | 2017 | 21445 | 0.040 |
Why?
|
| Cystectomy | 3 | 2011 | 623 | 0.040 |
Why?
|
| Exosomes | 1 | 2021 | 253 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 1489 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 2216 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2003 | 902 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 1994 | 4654 | 0.040 |
Why?
|
| Laminin | 1 | 1998 | 194 | 0.040 |
Why?
|
| Survival Analysis | 5 | 2012 | 9180 | 0.040 |
Why?
|
| Dissection | 1 | 2018 | 156 | 0.040 |
Why?
|
| Fibronectins | 1 | 1998 | 197 | 0.040 |
Why?
|
| Operative Time | 1 | 2018 | 217 | 0.040 |
Why?
|
| Endosonography | 1 | 2021 | 536 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1997 | 135 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 1998 | 259 | 0.040 |
Why?
|
| Stromal Cells | 2 | 2014 | 825 | 0.040 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2017 | 40 | 0.040 |
Why?
|
| Tissue Distribution | 3 | 2005 | 875 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 1538 | 0.040 |
Why?
|
| Recurrence | 1 | 2005 | 4758 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1997 | 182 | 0.040 |
Why?
|
| Diploidy | 1 | 1997 | 114 | 0.040 |
Why?
|
| Sialoglycoproteins | 1 | 1997 | 151 | 0.040 |
Why?
|
| Drinking Water | 1 | 2016 | 21 | 0.040 |
Why?
|
| Chimera | 1 | 2017 | 145 | 0.040 |
Why?
|
| Fatty Acid Synthase, Type I | 1 | 2016 | 11 | 0.040 |
Why?
|
| Polyploidy | 1 | 1997 | 73 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2021 | 550 | 0.040 |
Why?
|
| Receptors, Interleukin-8A | 1 | 2016 | 16 | 0.040 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1997 | 243 | 0.040 |
Why?
|
| Dasatinib | 1 | 2020 | 862 | 0.040 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2016 | 54 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2011 | 1533 | 0.040 |
Why?
|
| Carboplatin | 1 | 2019 | 823 | 0.040 |
Why?
|
| Water Pollutants, Chemical | 1 | 2016 | 37 | 0.040 |
Why?
|
| Kidney Neoplasms | 4 | 1997 | 3022 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2004 | 1616 | 0.030 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2017 | 100 | 0.030 |
Why?
|
| Homologous Recombination | 1 | 2017 | 185 | 0.030 |
Why?
|
| Proto-Oncogenes | 2 | 1994 | 202 | 0.030 |
Why?
|
| Protein Stability | 1 | 2017 | 370 | 0.030 |
Why?
|
| Adipose Tissue, White | 1 | 2016 | 99 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 524 | 0.030 |
Why?
|
| Pyrimidines | 2 | 2007 | 3518 | 0.030 |
Why?
|
| Epithelium | 4 | 2005 | 720 | 0.030 |
Why?
|
| Actins | 2 | 2016 | 608 | 0.030 |
Why?
|
| Hyperthyroidism | 1 | 1995 | 52 | 0.030 |
Why?
|
| Aneuploidy | 1 | 1997 | 369 | 0.030 |
Why?
|
| Diarrhea | 1 | 2019 | 686 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2004 | 2295 | 0.030 |
Why?
|
| Reperfusion | 1 | 1995 | 24 | 0.030 |
Why?
|
| Chromosome Aberrations | 2 | 2003 | 1960 | 0.030 |
Why?
|
| alpha-2-HS-Glycoprotein | 1 | 2015 | 10 | 0.030 |
Why?
|
| Cell Surface Display Techniques | 1 | 2015 | 17 | 0.030 |
Why?
|
| Karyotyping | 3 | 2008 | 1022 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2018 | 430 | 0.030 |
Why?
|
| Adenosine Deaminase | 1 | 2015 | 94 | 0.030 |
Why?
|
| Methylation | 1 | 2017 | 597 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2019 | 627 | 0.030 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2015 | 37 | 0.030 |
Why?
|
| Biomarkers | 5 | 2017 | 5047 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2009 | 2232 | 0.030 |
Why?
|
| Microsatellite Repeats | 3 | 2002 | 575 | 0.030 |
Why?
|
| Inpatients | 1 | 2020 | 678 | 0.030 |
Why?
|
| Dutasteride | 1 | 2014 | 10 | 0.030 |
Why?
|
| Organ Specificity | 3 | 2003 | 699 | 0.030 |
Why?
|
| Peptide Mapping | 1 | 2015 | 114 | 0.030 |
Why?
|
| Algorithms | 2 | 2010 | 3890 | 0.030 |
Why?
|
| Neutropenia | 1 | 2019 | 968 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2019 | 561 | 0.030 |
Why?
|
| Proteolysis | 1 | 2017 | 370 | 0.030 |
Why?
|
| Vimentin | 3 | 2008 | 253 | 0.030 |
Why?
|
| Iron | 1 | 1998 | 376 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2017 | 430 | 0.030 |
Why?
|
| Hepatocyte Growth Factor | 1 | 1995 | 142 | 0.030 |
Why?
|
| Transcription Factors | 2 | 2015 | 5270 | 0.030 |
Why?
|
| Consensus | 1 | 2019 | 978 | 0.030 |
Why?
|
| Mycobacterium leprae | 1 | 1994 | 16 | 0.030 |
Why?
|
| Oncogenes | 1 | 2018 | 673 | 0.030 |
Why?
|
| RNA Precursors | 1 | 2015 | 137 | 0.030 |
Why?
|
| Lysine | 1 | 2017 | 422 | 0.030 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 1994 | 82 | 0.030 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 2014 | 36 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 1995 | 157 | 0.030 |
Why?
|
| Paneth Cells | 1 | 2014 | 23 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2016 | 241 | 0.030 |
Why?
|
| Proteinuria | 1 | 2015 | 155 | 0.030 |
Why?
|
| Base Sequence | 4 | 2011 | 4917 | 0.030 |
Why?
|
| Histiocytes | 1 | 1994 | 94 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 4053 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 1618 | 0.030 |
Why?
|
| Adipocytes | 1 | 2016 | 305 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 846 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 1399 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 854 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 1995 | 661 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2018 | 1070 | 0.030 |
Why?
|
| Cell Division | 4 | 2000 | 2489 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 748 | 0.030 |
Why?
|
| Urology | 2 | 2001 | 128 | 0.030 |
Why?
|
| Genome | 1 | 2017 | 672 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2017 | 589 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1997 | 461 | 0.030 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2014 | 84 | 0.030 |
Why?
|
| Quinolines | 1 | 2017 | 383 | 0.030 |
Why?
|
| Anemia | 1 | 2019 | 689 | 0.030 |
Why?
|
| Androstadienes | 1 | 2014 | 165 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 550 | 0.030 |
Why?
|
| Endometrial Neoplasms | 1 | 2003 | 1341 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 886 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2011 | 2074 | 0.030 |
Why?
|
| Homozygote | 1 | 1995 | 717 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2019 | 923 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 1085 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1998 | 1688 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 6942 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 1972 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2007 | 3890 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2016 | 470 | 0.030 |
Why?
|
| 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2012 | 13 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 792 | 0.030 |
Why?
|
| DNA Replication | 1 | 2017 | 744 | 0.030 |
Why?
|
| Platinum | 1 | 2013 | 138 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 1084 | 0.030 |
Why?
|
| Abdomen | 1 | 1994 | 332 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 1999 | 2843 | 0.030 |
Why?
|
| Epilepsy | 1 | 2020 | 883 | 0.030 |
Why?
|
| Hyaluronan Synthases | 1 | 2012 | 20 | 0.030 |
Why?
|
| Prostatitis | 1 | 1992 | 18 | 0.030 |
Why?
|
| Annexin A4 | 1 | 2011 | 7 | 0.030 |
Why?
|
| Apolipoprotein E3 | 1 | 2011 | 16 | 0.030 |
Why?
|
| Integrin alpha4 | 1 | 2011 | 25 | 0.030 |
Why?
|
| Cathepsin B | 1 | 2011 | 32 | 0.030 |
Why?
|
| Casein Kinase Ialpha | 1 | 2011 | 16 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1945 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 1992 | 276 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2014 | 652 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2012 | 149 | 0.030 |
Why?
|
| Centrosome | 1 | 2012 | 95 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 607 | 0.030 |
Why?
|
| Imatinib Mesylate | 2 | 2007 | 1665 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2018 | 1026 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2015 | 1643 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1992 | 313 | 0.030 |
Why?
|
| Linear Models | 2 | 2009 | 1085 | 0.030 |
Why?
|
| Oncogene Fusion | 1 | 2011 | 63 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2012 | 208 | 0.020 |
Why?
|
| Hospitalization | 1 | 2020 | 2083 | 0.020 |
Why?
|
| Binding Sites | 1 | 1995 | 2171 | 0.020 |
Why?
|
| Imidazoles | 1 | 2017 | 999 | 0.020 |
Why?
|
| Length of Stay | 1 | 2018 | 1900 | 0.020 |
Why?
|
| Computational Biology | 1 | 2017 | 1271 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2014 | 829 | 0.020 |
Why?
|
| Decision Making | 1 | 2019 | 1287 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2003 | 367 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2011 | 392 | 0.020 |
Why?
|
| Seminal Vesicles | 2 | 2003 | 152 | 0.020 |
Why?
|
| RNA Interference | 1 | 2015 | 1408 | 0.020 |
Why?
|
| Kinetics | 2 | 2007 | 2049 | 0.020 |
Why?
|
| Granuloma | 1 | 1992 | 154 | 0.020 |
Why?
|
| Urogenital Surgical Procedures | 1 | 2010 | 16 | 0.020 |
Why?
|
| Cell Death | 1 | 2012 | 671 | 0.020 |
Why?
|
| Carrier Proteins | 2 | 2014 | 2022 | 0.020 |
Why?
|
| Mucins | 2 | 1988 | 285 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2015 | 1152 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1994 | 1005 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2016 | 1048 | 0.020 |
Why?
|
| Breast Neoplasms | 4 | 2017 | 15694 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2017 | 1549 | 0.020 |
Why?
|
| Electronics, Medical | 1 | 2009 | 15 | 0.020 |
Why?
|
| Chromosome Mapping | 3 | 1999 | 1471 | 0.020 |
Why?
|
| Nausea | 1 | 2011 | 525 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2002 | 528 | 0.020 |
Why?
|
| Histones | 1 | 2017 | 1466 | 0.020 |
Why?
|
| Alleles | 1 | 1995 | 2437 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 2011 | 246 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2010 | 275 | 0.020 |
Why?
|
| Protein Transport | 1 | 2011 | 734 | 0.020 |
Why?
|
| DNA Repair | 1 | 2017 | 1872 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 1439 | 0.020 |
Why?
|
| BCG Vaccine | 1 | 1992 | 399 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2011 | 345 | 0.020 |
Why?
|
| Transcriptome | 1 | 2017 | 1859 | 0.020 |
Why?
|
| Ligands | 1 | 2011 | 995 | 0.020 |
Why?
|
| Phenotype | 2 | 2010 | 6295 | 0.020 |
Why?
|
| Genetic Variation | 3 | 2004 | 2086 | 0.020 |
Why?
|
| Pancreatitis | 1 | 1991 | 267 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 4233 | 0.020 |
Why?
|
| Urination | 1 | 2008 | 36 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 2403 | 0.020 |
Why?
|
| Sutures | 1 | 2009 | 86 | 0.020 |
Why?
|
| Protein Binding | 1 | 2015 | 3438 | 0.020 |
Why?
|
| Isoantibodies | 1 | 2009 | 115 | 0.020 |
Why?
|
| Incidence | 3 | 2009 | 5673 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2008 | 170 | 0.020 |
Why?
|
| Reoperation | 1 | 1992 | 1382 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 1217 | 0.020 |
Why?
|
| Nerve Regeneration | 1 | 2008 | 105 | 0.020 |
Why?
|
| Penis | 1 | 2008 | 123 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2008 | 241 | 0.020 |
Why?
|
| Cytokines | 1 | 2017 | 2809 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2002 | 290 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2009 | 316 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2009 | 471 | 0.020 |
Why?
|
| World Health Organization | 1 | 1998 | 316 | 0.020 |
Why?
|
| Neoplasms, Vascular Tissue | 1 | 1987 | 12 | 0.020 |
Why?
|
| Urothelium | 1 | 1998 | 254 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2007 | 153 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 582 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 866 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 437 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 143 | 0.020 |
Why?
|
| Inulin | 1 | 2005 | 20 | 0.020 |
Why?
|
| Biotinylation | 1 | 2005 | 47 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2009 | 546 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2005 | 113 | 0.020 |
Why?
|
| Atrophy | 1 | 2006 | 261 | 0.020 |
Why?
|
| Leukemia, Myeloid | 1 | 1991 | 941 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2010 | 1681 | 0.020 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2005 | 52 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2010 | 778 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 3569 | 0.020 |
Why?
|
| Calbindin 2 | 1 | 2005 | 40 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2005 | 250 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2007 | 665 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 4549 | 0.020 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 2005 | 50 | 0.020 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2005 | 129 | 0.020 |
Why?
|
| Forecasting | 1 | 2007 | 694 | 0.020 |
Why?
|
| Family | 1 | 2009 | 736 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2010 | 1171 | 0.020 |
Why?
|
| Lasers | 1 | 2005 | 198 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 3260 | 0.020 |
Why?
|
| Receptors, Interleukin-11 | 1 | 2004 | 9 | 0.020 |
Why?
|
| Trinucleotide Repeats | 1 | 2004 | 106 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2005 | 869 | 0.020 |
Why?
|
| Cell Compartmentation | 1 | 2004 | 76 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 2054 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 3869 | 0.020 |
Why?
|
| Cell Communication | 1 | 2007 | 509 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2004 | 198 | 0.010 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1989 | 674 | 0.010 |
Why?
|
| Caenorhabditis elegans | 1 | 2005 | 268 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 2003 | 56 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 5539 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 448 | 0.010 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2005 | 170 | 0.010 |
Why?
|
| Acid Phosphatase | 2 | 1994 | 59 | 0.010 |
Why?
|
| Survivors | 1 | 2009 | 1031 | 0.010 |
Why?
|
| Thionucleotides | 1 | 2003 | 65 | 0.010 |
Why?
|
| Cysts | 1 | 2005 | 197 | 0.010 |
Why?
|
| Keratin-7 | 1 | 2003 | 52 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 2265 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2005 | 663 | 0.010 |
Why?
|
| Receptors, Neuropeptide | 1 | 2002 | 27 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2003 | 196 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 1991 | 1390 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2007 | 1038 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2003 | 542 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2005 | 602 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2002 | 169 | 0.010 |
Why?
|
| Mammary Glands, Animal | 1 | 2005 | 533 | 0.010 |
Why?
|
| Transgenes | 1 | 2004 | 557 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2004 | 501 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2009 | 1230 | 0.010 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2002 | 222 | 0.010 |
Why?
|
| Transcription Factor AP-2 | 1 | 2001 | 79 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 1544 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 1995 | 419 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 2 | 1995 | 2326 | 0.010 |
Why?
|
| Texas | 1 | 2012 | 6311 | 0.010 |
Why?
|
| Cell Line | 2 | 2003 | 5114 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2001 | 191 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2002 | 311 | 0.010 |
Why?
|
| Chromosome Breakage | 1 | 2001 | 226 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 2000 | 130 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 1487 | 0.010 |
Why?
|
| Estramustine | 1 | 2000 | 26 | 0.010 |
Why?
|
| X Chromosome | 1 | 2001 | 339 | 0.010 |
Why?
|
| Etoposide | 1 | 2002 | 870 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2000 | 212 | 0.010 |
Why?
|
| Galectin 1 | 1 | 1999 | 20 | 0.010 |
Why?
|
| Body Height | 1 | 2001 | 231 | 0.010 |
Why?
|
| Zinc Sulfate | 1 | 1999 | 8 | 0.010 |
Why?
|
| Respiratory Burst | 1 | 1999 | 23 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2001 | 566 | 0.010 |
Why?
|
| Metallothionein | 1 | 1999 | 34 | 0.010 |
Why?
|
| Pathology, Clinical | 1 | 2001 | 152 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2002 | 429 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2000 | 6100 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 1498 | 0.010 |
Why?
|
| Vinblastine | 1 | 2000 | 453 | 0.010 |
Why?
|
| Models, Biological | 2 | 2000 | 3254 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2004 | 1694 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1994 | 4638 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2000 | 335 | 0.010 |
Why?
|
| Neurokinin B | 1 | 1998 | 1 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 6207 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1998 | 256 | 0.010 |
Why?
|
| Gastrin-Releasing Peptide | 1 | 1998 | 6 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 980 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2004 | 1459 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1998 | 54 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2002 | 750 | 0.010 |
Why?
|
| Galectin 3 | 1 | 1999 | 138 | 0.010 |
Why?
|
| Diethylstilbestrol | 1 | 1998 | 109 | 0.010 |
Why?
|
| Stochastic Processes | 1 | 1997 | 44 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1998 | 95 | 0.010 |
Why?
|
| Proteomics | 1 | 2005 | 1380 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2000 | 476 | 0.010 |
Why?
|
| Nucleolus Organizer Region | 1 | 1997 | 17 | 0.010 |
Why?
|
| Ribs | 1 | 1998 | 91 | 0.010 |
Why?
|
| Goats | 1 | 1997 | 73 | 0.010 |
Why?
|
| Immune Sera | 1 | 1997 | 146 | 0.010 |
Why?
|
| Ilium | 1 | 1997 | 54 | 0.010 |
Why?
|
| Solutions | 1 | 1997 | 104 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2000 | 551 | 0.010 |
Why?
|
| Kidney Tubules | 1 | 1997 | 137 | 0.010 |
Why?
|
| Tissue Fixation | 1 | 1997 | 136 | 0.010 |
Why?
|
| Milk Proteins | 1 | 1997 | 116 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 1756 | 0.010 |
Why?
|
| Osteopontin | 1 | 1997 | 148 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1997 | 334 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1997 | 226 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1997 | 629 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 1998 | 423 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 4109 | 0.010 |
Why?
|
| Zymosan | 1 | 1995 | 10 | 0.010 |
Why?
|
| Phagocytes | 1 | 1995 | 44 | 0.010 |
Why?
|
| Triiodothyronine | 1 | 1995 | 77 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 3154 | 0.010 |
Why?
|
| Peroxides | 1 | 1995 | 12 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2001 | 2231 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1995 | 153 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2003 | 2086 | 0.010 |
Why?
|
| Malondialdehyde | 1 | 1995 | 47 | 0.010 |
Why?
|
| Body Weight | 1 | 2000 | 1293 | 0.010 |
Why?
|
| Peroxidase | 1 | 1995 | 132 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 1995 | 148 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1998 | 771 | 0.010 |
Why?
|
| DNA, Satellite | 1 | 1994 | 36 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2001 | 1656 | 0.010 |
Why?
|
| Specimen Handling | 1 | 1997 | 299 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1995 | 227 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 5687 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 1995 | 246 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 1997 | 598 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1995 | 406 | 0.010 |
Why?
|
| Point Mutation | 1 | 1997 | 769 | 0.010 |
Why?
|
| Software | 1 | 2002 | 1321 | 0.010 |
Why?
|
| Milk, Human | 1 | 1997 | 277 | 0.010 |
Why?
|
| Microscopy | 1 | 1995 | 182 | 0.010 |
Why?
|
| Urethral Diseases | 1 | 1994 | 36 | 0.010 |
Why?
|
| Exons | 1 | 1997 | 1328 | 0.010 |
Why?
|
| Receptors, Growth Factor | 1 | 1994 | 157 | 0.010 |
Why?
|
| Hamartoma | 1 | 1994 | 115 | 0.010 |
Why?
|
| Cell Survival | 1 | 1999 | 3045 | 0.010 |
Why?
|
| Genome, Human | 1 | 2001 | 1869 | 0.010 |
Why?
|
| DNA Primers | 1 | 1995 | 1399 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 1994 | 335 | 0.010 |
Why?
|
| Palpation | 1 | 1992 | 49 | 0.010 |
Why?
|
| Registries | 1 | 2000 | 2170 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 1998 | 1130 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2000 | 2483 | 0.010 |
Why?
|
| Sclerosis | 1 | 1992 | 84 | 0.010 |
Why?
|
| S100 Proteins | 1 | 1992 | 181 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1997 | 1555 | 0.010 |
Why?
|
| Cholelithiasis | 1 | 1991 | 43 | 0.010 |
Why?
|
| Neutrophils | 1 | 1995 | 835 | 0.010 |
Why?
|
| Muscles | 1 | 1992 | 416 | 0.010 |
Why?
|
| Smoking | 1 | 2000 | 2440 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1993 | 1323 | 0.010 |
Why?
|
| Collagen | 1 | 1994 | 752 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1995 | 509 | 0.010 |
Why?
|
| Liver Diseases | 1 | 1995 | 574 | 0.010 |
Why?
|
| Morbidity | 1 | 1991 | 397 | 0.010 |
Why?
|
| Homeostasis | 1 | 1995 | 950 | 0.010 |
Why?
|
| Stem Cells | 1 | 1996 | 1213 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 1995 | 1129 | 0.010 |
Why?
|
| Alcoholism | 1 | 1991 | 285 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 1989 | 220 | 0.000 |
Why?
|
| Necrosis | 1 | 1989 | 580 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1988 | 429 | 0.000 |
Why?
|
| Glioblastoma | 1 | 1997 | 1797 | 0.000 |
Why?
|
| Glioma | 1 | 1997 | 1963 | 0.000 |
Why?
|
| Urinary Bladder | 1 | 1989 | 575 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 2002 | 4557 | 0.000 |
Why?
|
| Receptor, ErbB-2 | 1 | 1994 | 2518 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1997 | 4849 | 0.000 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1991 | 2979 | 0.000 |
Why?
|
| Child | 1 | 1997 | 29154 | 0.000 |
Why?
|
| Adolescent | 1 | 1991 | 31252 | 0.000 |
Why?
|